S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
5 Hypergrowth Stocks to Buy Now (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
5 Hypergrowth Stocks to Buy Now (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
5 Hypergrowth Stocks to Buy Now (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
5 Hypergrowth Stocks to Buy Now (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
5 Hypergrowth Stocks to Buy Now (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
5 Hypergrowth Stocks to Buy Now (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
5 Hypergrowth Stocks to Buy Now (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
5 Hypergrowth Stocks to Buy Now (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
5 Hypergrowth Stocks to Buy Now (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
5 Hypergrowth Stocks to Buy Now (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
5 Hypergrowth Stocks to Buy Now (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
5 Hypergrowth Stocks to Buy Now (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
NASDAQ:NEO

NeoGenomics - NEO Price Target & Analyst Ratings

$17.41
-0.20 (-1.14%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$17.29
▼
$18.11
50-Day Range
$10.95
▼
$19.45
52-Week Range
$6.00
▼
$19.51
Volume
1.70 million shs
Average Volume
1.33 million shs
Market Capitalization
$2.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.89

NeoGenomics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 10 Analyst Ratings

Consensus Analyst Price Target

$18.89
8.49% Upside
High Prediction$21.00
Average Prediction$18.89
Low Prediction$15.00
TypeCurrent
4/1/22 to 4/1/23		1 Month Ago
3/2/22 to 3/2/23		3 Months Ago
1/1/22 to 1/1/23		1 Year Ago
4/1/21 to 4/1/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
Hold
2 Hold rating(s)
4 Hold rating(s)
6 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$18.89$19.17$19.00$25.36
Predicted Upside8.49% Upside28.81% Upside39.63% Upside18.30% Upside
Get NeoGenomics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.

NEO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NEO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

NeoGenomics Stock vs. The Competition

TypeNeoGenomicsMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.64
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside8.49% Upside1,994.88% Upside97.24% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/3/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight$18.00 ➝ $20.00+15.34%
2/24/2023Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$15.00 ➝ $21.00+30.43%
2/24/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$12.00 ➝ $19.00+18.01%
2/24/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetEqual Weight$17.00 ➝ $18.00+11.80%
2/24/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$14.00 ➝ $20.00+20.26%
2/24/2023Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy$20.00+20.26%
11/15/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$17.00+50.98%
11/9/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$12.00 ➝ $15.00+68.54%
10/28/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating		B. Weinstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOutperform
8/15/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeNeutral
8/10/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$18.00 ➝ $20.00+68.63%
3/29/2022Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOverweight ➝ Equal Weight$34.00 ➝ $16.00-10.06%
3/29/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral$25.00 ➝ $18.00+1.18%
2/24/2022Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$46.00 ➝ $30.00+61.99%
1/27/2021Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$65.00+21.43%
10/26/2020CIBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeOutperformer$10.50 ➝ $14.50-65.02%
8/28/2020Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$46.00+21.95%
(Data available from 4/1/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












NEO Price Target - Frequently Asked Questions

What is NeoGenomics's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for NeoGenomics stock is Moderate Buy based on the current 2 hold ratings and 8 buy ratings for NEO. The average twelve-month price prediction for NeoGenomics is $18.89 with a high price target of $21.00 and a low price target of $15.00. Learn more on NEO's analyst rating history.

Do Wall Street analysts like NeoGenomics more than its competitors?

Analysts like NeoGenomics more than other Medical companies. The consensus rating for NeoGenomics is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how NEO compares to other companies.

Is NeoGenomics being upgraded by Wall Street analysts?

Over the previous 90 days, NeoGenomics's stock had 2 upgrades by analysts.

Does NeoGenomics's stock price have much upside?

According to analysts, NeoGenomics's stock has a predicted upside of 28.15% based on their 12-month price targets.

What analysts cover NeoGenomics?

NeoGenomics has been rated by Benchmark, Cowen, Morgan Stanley, Needham & Company LLC, Piper Sandler, and Raymond James in the past 90 days.


Stock Ratings Reports and Tools

Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
Ratings for Popular Stocks:
This page (NASDAQ:NEO) was last updated on 4/1/2023 by MarketBeat.com Staff